Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04464759
Title A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ravi Amaravadi, MD
Indications

melanoma

Therapies

Nivolumab

Hydroxychloroquine + Ipilimumab + Nivolumab

Hydroxychloroquine + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.